Stop using nowDrug recall · FDA · Published April 26, 2023
Gadget Island DYNAMITE SUPER Capsules: Unapproved Drug Risk
Gadget Island recalls 58,000 mg DYNAMITE SUPER capsules due to unapproved drug ingredients. FDA found undeclared sildenafil and tadalafil, making it an illegal product.
Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared sildenafil and tadalafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Take action
Contact the company
📍Recalling firmGadget Island, Inc1275 Halyard Dr Ste 175 · West Sacramento, CA 95691
✎ GovInfoNow plain-language explainer
Gadget Island is recalling 58,000 mg DYNAMITE SUPER capsules because they contain undeclared sildenafil and tadalafil, which are approved drugs for male sexual enhancement. This makes the product an unapproved drug that could cause health risks. Read more at govinfonow.com/recall/33672-gadget-island-dynamite-super-capsules-unapproved-drug-risk.
“Gadget Island DYNAMITE SUPER Capsules: Unapproved Drug Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/33672-gadget-island-dynamite-super-capsules-unapproved-drug-risk. Based on FDA recall #D-0573-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0573-2023%22&limit=1).
The FDA announced on April 26, 2023, that Gadget Island, Inc. is recalling DYNAMITE SUPER capsules after analysis found them tainted with undeclared sildenafil and tadalafil. The agency classified the recall as Class I due to the risk posed by these unapproved drug ingredients.
How to tell if you have it
Brand: Gadget Island
Product: DYNAMITE SUPER capsule, 58,000 MG, 1-count blister card, Made in America
UPC: 6 75799 37602 7
Lot/Item#: OMS760-B
Expiration: 12/2025
Quantity: 140 blister packs
The hazard
FDA analysis found the product to be tainted with undeclared sildenafil and tadalafil, ingredients found in FDA approved products for the treatment of male sexual enhancement. This makes the product an unapproved drug marketed without an Approved NDA/ANDA.
Context
GovInfoNow's records show Gadget Island, Inc has 1 other recall on record since 2017-09-15. On 2017-09-15, the company recalled Gadget Island grande X 5800 Capsules due to undeclared Active Pharmaceutical Ingredients sildenafil, desmethyl carbodenafil and tadalafil. Other recent recalls of similar products include StuffbyNainax MR 7 SUPER 700000 Capsules (2025-12-15), Buy-Herbal Kian Pee Wan Capsules Recall (2026-03-21), and Agebox iKids-Growth Day Formula Capsules (2025-10-28).
How to tell if you have this one
Look for the DYNAMITE SUPER capsules with 58,000 mg, 1-count blister card, made in America, UPC 6 75799 37602 7. The lot number is OMS760-B with an expiration date of 12/2025.
Brand
Gadget Island
Product
DYNAMITE SUPER capsule, 58,000 MG, 1-count blister card, Made in America, UPC 6 75799 37602 7
Category
Drug
FDA recall event · 3 products
All 3 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
Classification
Class I
Status
Ongoing
Distribution
Nationwide in the USA.
Recall number
Product, codes & lots
Quantity
D-0571-2023
Pro Power Knight Plus capsule, 2550mg, 1-count blister card, Distributed by Beyond Health and youth Inc, Seattle, WA 98110, UPC 4 94922 90522 0.; No lot number, Exp: 06/2026
628 blister cards
D-0572-2023
NUX Male Enhancement capsule, 1-count blister card, distributed by SX Power CO., Chicago, Il 60612, UPC 6 01577 51236 3.; Lot#: RO 927996, Exp: 12/25/2024
18 blister cards
D-0573-2023
DYNAMITE SUPER capsule, 58,000 MG, 1-count blister card, Made in America, UPC 6 75799 37602 7.; Lot/Item#: OMS760-B, Exp: 12/2025
140 blister packs
Based on the official FDA remedy
What to do — step by step
Stop Using Now
Immediately stop using the DYNAMITE SUPER capsules as they contain unapproved drugs that could cause health risks.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 14 days after the firm started it.
1Firm started the recall
2Published in FDA’s Enforcement Report
3FDA classified it Class I
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0573-2023 (April 26, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0573-2023 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.